USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Mitsubishi Tanabe Pharma Corporation

USPTO PatentsView assignee record - 96 granted patents across 17 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

16.1

Avg claims per patent

-22%

5-year filing velocity

The verdict

Mitsubishi holds 96 US patents across 17 technology areas, rank #3,781 of 50,000 tracked assignees.

#3,781
of 50,000 US assignees by volume: Top 14%
by Innovation Score (49.9/100): 16.1
avg claims per patent: -22%
filing velocity, last 5 yrs

Portfolio overview

Mitsubishi Tanabe Pharma Corporation has been granted 96 US utility patents between 2015 and 2025, placing Mitsubishi Tanabe Pharma Corporation at rank #3,781 across all assignees tracked by PlainPatent. This portfolio spans 17 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.1 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Mitsubishi Tanabe Pharma Corporation is one of the more focused assignees in the PatentsView dataset. By volume, Mitsubishi sits between John Bean Technologies Corporation (96 patents, rank #3,777) and Suncoke Technology AND Development Llc (96 patents, rank #3,785) - the closest US assignees by grant volume. The composite Innovation Score of 49.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 42 grants, compared with 54 in the 2015–2019 window, a -22% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Mitsubishi Tanabe Pharma Corporation's 16.1 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 17 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Mitsubishi Tanabe Pharma Corporation against peers pursuing similar technology classes.

John Bean

96
Karma Automotive

96
Knoll

96
Lite-on OPTO Tech…

96
Rogers

96
Rosemount TANK Ra…

96
Shenzhen SNC OPTO

96
Suncoke Technolog…

96
Mitsubishi Tanabe… ◀

96

What this shows Mitsubishi holds 96 patents at rank #3,781, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Mitsubishi

By rank, the assignees closest to #3,781 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Mitsubishi's primary technology class.

Mitsubishi's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

50 Top 14% higher than 86% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Mitsubishi Tanabe Pharma Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	15	15.6%
2016	8	8.3%
2017	15	15.6%
2018	9	9.4%
2019	7	7.3%
2020	3	3.1%
2021	7	7.3%
2022	8	8.3%
2023	9	9.4%
2024	8	8.3%
2025	7	7.3%

Which technologies does Mitsubishi Tanabe Pharma Corporation patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 84

C07D - HETEROCYCLIC COMPOUNDS 57

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 53

C07K - PEPTIDES 13

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 10

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 8

Y02P - CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS 6

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 5

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 4

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 4

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 3

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 3

C12Y - ENZYMES 2

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 1

A61J - CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE 1

Top 15 of 17 technology areas

Patent Moat Analysis

Portfolio Volume Light

Tech Breadth Focused

Claim Depth Standard

Velocity Declining

Where it ranks

Overall rank by patents

#3,781

Across all tracked assignees

Innovation Score

49.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Mitsubishi Tanabe Pharma Corporation hold?

Mitsubishi Tanabe Pharma Corporation holds 96 US granted patents filed between 2015 and 2025, spanning 17 technology areas.

What is Mitsubishi Tanabe Pharma Corporation's Innovation Score?

Mitsubishi Tanabe Pharma Corporation has an Innovation Score of 49.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Mitsubishi Tanabe Pharma Corporation focus on?

Mitsubishi Tanabe Pharma Corporation's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 84 patents. The company has filed patents in 17 CPC subclasses total.

Is Mitsubishi Tanabe Pharma Corporation's patent filing rate increasing or decreasing?

Mitsubishi Tanabe Pharma Corporation's recent filing velocity is -22% compared to the prior five-year period. Filing activity has slowed relative to earlier years.

What does claim depth mean for Mitsubishi Tanabe Pharma Corporation's patents?

Mitsubishi Tanabe Pharma Corporation's patents average 16.1 claims each. This falls within the standard range, providing solid legal coverage.

How is the Mitsubishi Tanabe Pharma Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Mitsubishi's 96 grants land it in the top 14% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Mitsubishi ranks #3,781 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.